PhD conferral Angelo K. Romasanta - online
Link, Merge, Grow: How Academia, SMEs and Big Pharma Seized Opportunities in Fragment-Based Drug Discovery
Angelo K. Romasanta
Prof.dr. J.E. van Muijlwijk-Koezen & Prof.dr. P.C. van der Sijde
Amsterdam Institute of Molecular and Life Sciences
Fragment-based drug discovery (FBDD) is a recently mainstream approach in the pharmaceutical sciences used to generate the starting chemical matter in the early stages of drug discovery. While it received high expectations on its potential to transform hit screening, the industry was slow to adopt FBDD due to skepticism and investment in traditional approaches such as high-throughput screening. In this research, we explore how various actors contributed to the emergence and development of the field, using various data sources including publications, interviews, firm profiles and researcher CVs. We analyze new ventures, big pharma and academia in FBDD to offer insights on how pioneers can seize opportunities in novel fields.